Contact this trialFirst, we need to learn more about you.
Janus Kinase (JAK) Inhibitor
Deucravacitinib for Nail Psoriasis
Recruiting1 awardPhase < 1
Birmingham, Alabama
This trial will test the effectiveness and safety of deucravactinib in treating nail psoriasis in 20 adult patients. Patients will take deucravacitinib daily for
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.